Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis

Haemostasis

Volumn 31, Issue 2, 2001, Pages 99-105

  Gemmati, Donato ^a   Serino, M L ^a   Moratelli, S ^a   Tognazzo, S ^a   Ongaro, A ^a   Scapoli, G L ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Combined defects; Factor V G1691A; Gene environment interaction; Inherited thrombophilia; Prothrombin G20210A

Indexed keywords

BLOOD CLOTTING FACTOR 5; PROTEIN C; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FAMILIAL DISEASE; FEMALE; FRACTURE; GENE MUTATION; HETEROZYGOSITY; HUMAN; INHERITANCE; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; THROMBOEMBOLISM; THROMBOSIS;

EID: 0035742790     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048050     Document Type: Article

References (29)

1. Inherited thrombophilia: Part 1
2. Inherited thrombophilia: Part 2
3. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
4. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
5. Mutation in blood coagulation factor V associated with resistance to activated protein C
6. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
7. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C
8. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
9. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis
10. Management of patients with hereditary hypercoagulable disorders
11. Multiple analysis of three common genetic alterations associated with thrombophilia
12. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family
13. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation
14. The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency
15. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency
16. Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele), in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome - A case report
17. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
18. A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype
19. Multiplex PCR-mediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene
20. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects
21. Epidemiology of factor V Leiden: Clinical implications
22. Geographic distribution of the 20210 G to A prothrombin variant
23. Resistance to activated protein C and low levels of protein S activity in nine thrombophilic families: A correct diagnosis
24. Different anticoagulant response to activated protein C (APC test) and to Agkistrodon contortrix venom (ACV test) in a family with FV-R506Q substitution
25. Activated protein C resistance: From phenotype to genotype and clinical practice
26. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
27. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families
28. Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
29. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism